ReShape Lifesciences Inc. [RSLS] stock is trading at $0.22, up 6.51%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The RSLS shares have gain 9.40% over the last week, with a monthly amount drifted -7.05%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
ReShape Lifesciences Inc. [RSLS] stock has fluctuated between $0.14 and $1.66 over the past year. ReShape Lifesciences Inc. [NASDAQ: RSLS] shares were valued at $0.22 at the most recent close of the market.
Analyzing the RSLS fundamentals
ReShape Lifesciences Inc. [NASDAQ:RSLS] reported sales of 8.34M for the trailing twelve months, which represents a drop of -15.00%. Gross Profit Margin for this corporation currently stands at 0.66% with Operating Profit Margin at -1.34%, Pretax Profit Margin comes in at -1.3%, and Net Profit Margin reading is -1.31%. To continue investigating profitability, this company’s Return on Assets is posted at -1.33, Equity is -2.08 and Total Capital is -2.37. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.05.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.1844 points at the first support level, and at 0.1511 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.2686, and for the 2nd resistance point, it is at 0.3195.
Ratios To Look Out For
For context, ReShape Lifesciences Inc.’s Current Ratio is 2.24. Further, the Quick Ratio stands at 1.26, while the Cash Ratio is 0.7. Considering the valuation of this stock, the price to sales ratio is 0.61, the price to book ratio is 1.13.
Transactions by insiders
Recent insider trading involved STANKOVICH THOMAS, Chief Financial Officer, that happened on Oct 25 ’23 when 131.0 shares were sold. Chief Financial Officer, STANKOVICH THOMAS completed a deal on Oct 11 ’23 to sell 39.0 shares. Meanwhile, Chief Financial Officer STANKOVICH THOMAS sold 118.0 shares on Sep 01 ’23.
